Therapeutics News and Research

RSS

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.

8 Dec 2014

Promising anti-malarial compound uses novel mechanism to kill malaria parasite

An international research collaborative has determined that a promising anti-malarial compound tricks the immune system to rapidly destroy red blood cells infected with the malaria parasite but leave healthy cells unharmed. St. Jude Children's Research Hospital scientists led the study, which appears in the current online early edition of the Proceedings of the National Academy of Sciences.

5 Dec 2014

Cellular Research announces commercial availability of Precise targeted RNASeq assays

Cellular Research today announced the commercial launch of its Precise targeted RNASeq assays. The company also announced the commercial availability of application-focused panels for the Precise assays, including panels designed for oncology, induced pluripotent stem cells and immunology.

5 Dec 2014

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc., has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide.

5 Dec 2014

Scientists seek to improve stem cell transplant outcomes using DNA sequencing, mathematical modeling

Is the human immune system similar to the weather, a seemingly random yet dynamical system that can be modeled based on past conditions to predict future states? Scientists at VCU Massey Cancer Center's award-winning Bone Marrow Transplant (BMT) Program believe it is, and they recently published several studies that support the possibility of using next-generation DNA sequencing and mathematical modeling to not only understand the variability observed in clinical outcomes of stem cell transplantation, but also to provide a theoretical framework to make transplantation a possibility for more patients who do not have a related donor.

5 Dec 2014

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

While aptamers—single-stranded nucleic acids—offer promise as drug-delivery tools for cancer treatment, it has proven difficult to get them to tumor cells at therapeutic levels.

4 Dec 2014

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.

4 Dec 2014

MIT engineers create new computer model to design complex 3-D DNA shapes

MIT biological engineers have created a new computer model that allows them to design the most complex three-dimensional DNA shapes ever produced, including rings, bowls, and geometric structures such as icosahedrons that resemble viral particles.

3 Dec 2014

Researchers identify possible prognostic biomarker in triple-negative breast cancer

"Triple-negative" breast cancer (TNBC) occurs in patients whose cells do not express receptors for estrogen, progesterone, and/or human epidermal growth factor receptor 2 (ER-/PR-/HER2-).

2 Dec 2014

Global stem cell market estimated to reach US$117.66B in 2018

Stem cells have the potential to transform healthcare by enabling the cost-effective treatment of many conditions that currently have poor treatment options.

2 Dec 2014

CASyM publishes European implementation strategy for Systems Medicine

After a two year cross-disciplinary consultation process the Coordinating Action Systems Medicine (CASyM) published its European implementation strategy (roadmap) for Systems Medicine.

2 Dec 2014

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

New research published in the December 2014 issue of the Journal of Leukocyte Biology, shows that a component found in in the plant, Glycyrrhiza uralensis, may inhibit the development of metabolic disorders by stopping the activation of NLRP3, a protein involved in the disease process.

2 Dec 2014

Sanford-Burnham, Mayo Clinic scientists to jointly find new treatment for resistant hypertension

Sanford-Burnham Medical Research Institute at Lake Nona and Mayo Clinic today announced that a joint team of scientists has been selected as a winner of GlaxoSmithKline's 2014 Discovery Fast Track Challenge.

2 Dec 2014

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport Syndrome was first described by a physician called Cecil Alport, back in the late 1920s. It's a genetic disease that affects a certain type of collagen involved in the functioning of the kidney, the ear, and the eye.

1 Dec 2014

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Nektar Therapeutics reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

From Baxter International Inc. 1 Dec 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Pivotal Therapeutics Inc., ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its accomplishments and financial results for the three months ended September 30, 2014.

29 Nov 2014

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

The U.S. Food and Drug Administration is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids, which is in keeping with Kalorama Information's view that in the female health market there is much room for improvement both in the development of products and the treatment of diseases.

29 Nov 2014

Study provides proof of concept for developing antibodies against human pathogens

Scientists investigating the potentially deadly hantavirus have used a novel approach to developing protective antibodies against it. Their work, published in today's online edition of Science Translational Medicine, provides proof of concept for producing antibodies against a broad range of human pathogens.

28 Nov 2014

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.

27 Nov 2014

Therapeutics News and Research

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

Promising anti-malarial compound uses novel mechanism to kill malaria parasite

Cellular Research announces commercial availability of Precise targeted RNASeq assays

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Scientists seek to improve stem cell transplant outcomes using DNA sequencing, mathematical modeling

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

MIT engineers create new computer model to design complex 3-D DNA shapes

Researchers identify possible prognostic biomarker in triple-negative breast cancer

Global stem cell market estimated to reach US$117.66B in 2018

CASyM publishes European implementation strategy for Systems Medicine

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

Sanford-Burnham, Mayo Clinic scientists to jointly find new treatment for resistant hypertension

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

iCo Therapeutics announces corporate update and Q3 2014 financial results

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

Study provides proof of concept for developing antibodies against human pathogens

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News